Grace Therapeutics
Grace Therapeutics is a late-stage biopharma with a target PDUFA date of 2Q'26 for GTx-104. GTx-102 ready to initiative pivotal Ph 3. Partnership opportunities including in-licensing CNS, immunology and oncology.
)
January 11-14, 2027 | San Francisco
January 11-14, 2027 | San Francisco
)
)
January 11-14, 2027 | San Francisco
){kind=logo}
){kind=logo}
)